NDAORAL-28TABLET
Approved
Jan 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
NOR-QD (norethindrone) by Teva is clinical pharmacology 1. First approved in 1973.
Drug data last refreshed 15h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOR-QD (norethindrone) is a progestin-only oral contraceptive approved in 1973 that prevents conception through ovulation suppression, cervical mucus thickening, and endometrial alteration. It is indicated for contraception, heavy menstrual bleeding, endometriosis, and uterine fibroids. The drug is rapidly absorbed with peak plasma concentrations in 1-2 hours and has an elimination half-life of approximately 8 hours.
LOE Approaching
As a legacy product approaching loss of exclusivity, NOR-QD faces significant genericization pressure with limited growth opportunities and likely smaller dedicated brand teams focused on maintenance and managed care.
Mechanism of Action
CLINICAL PHARMACOLOGY 1. Mode of Action. Nora-BE progestin-only oral contraceptives prevent conception by suppressing ovulation in approximately half of users, thickening the cervical mucus to inhibit sperm penetration, lowering the mid-cycle LH and FSH peaks, slowing the movement of the ovum…
Worked on NOR-QD at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.